Personalized kidney care: Biomarker-Guided treatment aims to slow disease

NCT ID NCT07239570

Recruiting now Disease control Sponsor: Peter Rossing Source: ClinicalTrials.gov ↗

First seen Nov 20, 2025 · Last updated May 02, 2026 · Updated 25 times

Summary

This study tests whether using specific biomarkers to choose treatments can better slow kidney function decline in people with chronic kidney disease (CKD) compared to standard care. About 125 adults with CKD and elevated albumin in their urine will receive either biomarker-guided therapy or usual care. The goal is to see if this personalized approach preserves kidney function over two years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hospital Clinico de Valencia
NOT_YET_RECRUITING

Valencia, Spain

Contact Phone: •••-•••-•••• Email: •••••@•••••
Lund University
NOT_YET_RECRUITING

Malmö, Sweden

Contact Phone: •••-•••-•••• Email: •••••@•••••
Steno Diabetes Center Copenhagen
RECRUITING

Herlev, Denmark

Contact Phone: •••-•••-•••• Email: •••••@•••••
University Medical Center Hamburg-Eppendorf
NOT_YET_RECRUITING

Hamburg, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHRONIC KIDNEY DISEASE(CKD)